Related Experiment Video
Updated: Dec 7, 2025

Assessment of the Metabolic Profile of Primary Leukemia Cells
Published on: November 21, 2018
Tumor microenvironment changes tumor cell sensitivity to action of energy metabolism modifiers
O N Pyaskovskaya1, D L Kolesnik1, I V Prokhorova1
1R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology, NAS of Ukraine, Kyiv 03022, Ukraine.
Background:
Taking into account differences in the bioenergetics between malignant and normal cells a search of antitumor drugs among the modifiers of tumor metabolism has a reasonable excuse. Earlier it was found that the cytotoxic/cytostatic action of sodium dichloroacetate (DCA) against Lewis lung carcinoma (LLC) cells in vitro was enhanced in the case of its combination with metformin (MTF).
Aim:
To study the antitumor action of DCA in combination with MTF against LLC in vivo.
Materials And Methods:
LLC/R9, a low metastatic variant of LLC cells, was used. LLC/R9 bearing mice were treated with MTF (at a total dose 0.15 g/kg b.w.) alone or in combination with DCA (at a total dose of 0.75 g/kg b.w.). LLC/R9 growth kinetics and the primary tumor growth and metastasis indices on the 23rd day after tumor cell inoculation were evaluated by routine procedures. The state of the electron transport chain of mitochondria in tumor cells was studied using electron paramagnetic resonance. The content of lactate and glucose in blood plasma from mice was measured by enzymatic methods using biochemical analyzer. The number of tumor-associated macrophages (TAMs) and their distribution by M1/M2 phenotype were estimated by flow cytometry using antibodies against CD68 and CD206.
Results:
In LLC/R9-bearing mice treated with DCA in combination with MTF, tumor growth and metastasis indices, as well as circulating glucose and lactate levels were not significantly different from those in the control group. The level of nitrosylation of non-heme and heme proteins and the content of iron-sulfur centers in the mitochondria of tumor cells in LLC/R9-bearing mice administered with DCA in combination with MTF did not also differ from the corresponding indices in control. Instead, in tumors treated with MTF alone and in combination with DCA the total CD68+ TAMs count was almost 27% (p < 0.05) and 43% lower (p < 0.05) correspondingly than that in control, but this decrease was not accompanied by redistribution of CD68+/CD206+ and CD68+/D206- subsets.
Conclusion:
DCA in combination with MTF, at least in doses applied, did not affect LLC/R9 growth and metastasis in vivo. The complete absence of an antitumor effect of DCA in combination with MTF was simultaneously associated with the absence of significant changes in the functional state of electron transport chain of mitochondria in tumor cells, circulating glucose and lactate levels, and the decrease of the TAMs amount in tumors. It suggests that the antitumor activity of DCA and MTF could be determined by both their local effects within a tumor and their multiple systemic impacts.
Insights
Sodium dichloroacetate (DCA) and metformin (MTF) did not inhibit Lewis lung carcinoma (LLC) growth or metastasis in vivo. This combination therapy showed no significant impact on tumor bioenergetics or immune cell populations, suggesting limited therapeutic potential.
Area of Science:
- Oncology
- Cancer Metabolism
- Drug Discovery
Background:
- Tumor cells exhibit distinct bioenergetics compared to normal cells, justifying the search for antitumor drugs targeting metabolic pathways.
- Sodium dichloroacetate (DCA) and metformin (MTF) have shown potential in modifying tumor metabolism.
- Previous in vitro studies indicated enhanced cytotoxic/cytostatic effects of DCA combined with MTF against Lewis lung carcinoma (LLC) cells.
Purpose of the Study:
- To investigate the in vivo antitumor efficacy of combining DCA and MTF against LLC.
- To evaluate the impact of this combination therapy on tumor growth, metastasis, and key cellular and metabolic markers.
Main Methods:
- LLC/R9 cells were inoculated into mice, followed by treatment with MTF alone or in combination with DCA.
- Tumor growth and metastasis were assessed, alongside mitochondrial electron transport chain function using electron paramagnetic resonance.
- Blood glucose and lactate levels, and tumor-associated macrophage (TAM) populations (M1/M2 phenotype) were quantified.
Main Results:
- The combination of DCA and MTF did not significantly alter LLC/R9 tumor growth or metastasis indices compared to controls.
- No significant changes were observed in mitochondrial function, circulating glucose/lactate levels, or protein nitrosylation.
- A significant reduction in total TAMs was noted in tumors treated with MTF alone and in combination with DCA, but without altering M1/M2 subset distribution.
Conclusions:
- DCA combined with MTF demonstrated no significant antitumor effect on LLC growth and metastasis in vivo at the tested doses.
- The lack of efficacy correlated with unchanged mitochondrial function, metabolic markers, and TAM populations.
- The study suggests that the potential antitumor activity of DCA and MTF may involve both local and systemic effects, which were not sufficiently modulated in this model.
More Related Videos
Related Concept Videos
The Tumor Microenvironment
Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Treatment Resistant Cancers
Tumor Immunotherapy
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

